| BMY |
Bristol-Myers Squibb Company |
72%
|
. Following any such strategic transaction, we may not achieve any expected synergies to justify the transaction. For example, such transactions may require us to incur non-recurring or other charges… |
| BMY |
Bristol-Myers Squibb Company |
72%
|
Reciprocal relationship from BMY graph: Reciprocal relationship from MPLT graph: . Following any such strategic transaction, we may not achieve any expected synergies to justify the transaction. For … |
| BMYMP |
Bristol-Myers Squibb Co |
72%
|
. Following any such strategic transaction, we may not achieve any expected synergies to justify the transaction. For example, such transactions may require us to incur non-recurring or other charges… |
| BMYMP |
Bristol-Myers Squibb Co |
72%
|
Reciprocal relationship from BMYMP graph: Reciprocal relationship from MPLT graph: . Following any such strategic transaction, we may not achieve any expected synergies to justify the transaction. Fo… |
| JNJ |
Johnson & Johnson |
72%
|
Reciprocal relationship from JNJ graph: Reciprocal relationship from MPLT graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from MPLT graph: . Following any such strategic transa… |
| JNJ |
Johnson & Johnson |
72%
|
. Following any such strategic transaction, we may not achieve any expected synergies to justify the transaction. For example, such transactions may require us to incur non-recurring or other charges… |
| NBIX |
Neurocrine Biosciences, Inc. |
72%
|
. Following any such strategic transaction, we may not achieve any expected synergies to justify the transaction. For example, such transactions may require us to incur non-recurring or other charges… |
| NBIX |
Neurocrine Biosciences, Inc. |
72%
|
Reciprocal relationship from NBIX graph: Reciprocal relationship from MPLT graph: Reciprocal relationship from NBIX graph: Reciprocal relationship from MPLT graph: . Following any such strategic tran… |
| NMRA |
Neumora Therapeutics, Inc. |
72%
|
. Following any such strategic transaction, we may not achieve any expected synergies to justify the transaction. For example, such transactions may require us to incur non-recurring or other charges… |
| NMRA |
Neumora Therapeutics, Inc. |
72%
|
Reciprocal relationship from NMRA graph: Reciprocal relationship from MPLT graph: . Following any such strategic transaction, we may not achieve any expected synergies to justify the transaction. For… |
| SNYNF |
Sanofi |
72%
|
incident, third parties may gather, collect or infer sensitive data about us from public sources, data brokers or other means that reveal competitively sensitive details about our organization and co… |
| SNYNF |
Sanofi |
72%
|
Reciprocal relationship from SNYNF graph: Reciprocal relationship from MPLT graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from MPLT graph: Reciprocal relationship from SNYN… |
| ACAD |
ACADIA Pharmaceuticals Inc. |
62%
|
Reciprocal relationship from ACAD graph: Reciprocal relationship from MPLT graph: Reciprocal relationship from ACAD graph: Reciprocal relationship from MPLT graph: Reciprocal relationship from ACAD g… |
| ACADIA-PHARMACEUTICALS-INC |
ACADIA-PHARMACEUTICALS-INC |
62%
|
. Following any such strategic transaction, we may not achieve any expected synergies to justify the transaction. For example, such transactions may require us to incur non-recurring or other charges… |
| ALVARADO-THERAPEUTICS-INC |
ALVARADO-THERAPEUTICS-INC |
62%
|
d legislation and implemented regulations that are designed to control pharmaceutical and biological product pricing, including price or reimbursement constraints, discounts, restrictions on certain … |
| SYREMIS-THERAPEUTICS-LTD |
SYREMIS-THERAPEUTICS-LTD |
62%
|
. Following any such strategic transaction, we may not achieve any expected synergies to justify the transaction. For example, such transactions may require us to incur non-recurring or other charges… |
